Skip to main content

Table 3 Change from baseline at week 16 in non-work activities and work productivity

From: Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis

 

Placebo (n = 514)

Tanezumab 2.5 mg (n = 514)

Tanezumab 5 mg (n = 517)

Non-work activities

 Percent activity impairment

  n

448

476

482

  LS mean (SE) change from baseline

−23.49 (1.22)

− 29.41 (1.20)

− 29.45 (1.19)

  Difference in LS means (95% CI)

 

−5.92 (−8.87, − 2.98)

−5.96 (− 8.89, − 3.02)

  p value

 

< 0.0001

< 0.0001

Work productivity

 Percent work time missed

  n

127

142

126

  LS mean (SE) change from baseline

−0.20 (1.19)

−0.86 (1.16)

− 3.60 (1.21)

  Difference in LS means (95% CI)

 

−0.66 (−3.63, 2.32)

− 3.40 (− 6.47, − 0.34)

  p value

 

0.6637

0.0294

 Percent impairment while working

  n

124

140

125

  LS mean (SE) change from baseline

−18.59 (2.29)

−25.94 (2.22)

−26.46 (2.31)

  Difference in LS means (95% CI)

 

−7.34 (−13.01, − 1.68)

−7.87 (− 13.71, − 2.03)

  p value

 

0.0112

0.0084

 Percent overall work impairment

  n

124

140

125

  LS mean (SE) change from baseline

−19.12 (2.33)

−26.56 (2.26)

−27.49 (2.36)

  Difference in LS means (95% CI)

 

−7.44 (−13.22, − 1.67)

−8.37 (−14.32, − 2.42)

  p value

 

0.0116

0.0060

  1. Observed data, WPAI-OA of the Knee or Hip v2.0 questionnaire. All patients completed the activity impairment item. Those currently employed also completed work time missed, impairment while working and overall work impairment items. ANCOVA model included the following independent variables for Study 1 vs Study 2, index joint stratification factor, baseline response to question, baseline diary average pain score, and treatment
  2. ANCOVA Analysis of covariance, CI Confidence interval, LS Least squares, SE Standard error, WPAI-OA Work Productivity and Activity Impairment-osteoarthritis